Prostate cancer (PCa) affects millions of men globally. Due to advances in understanding
genomic landscapes and biological functions, the treatment of PCa continues to improve …

Androgen receptor (AR) is a steroid receptor transcriptional factor for testosterone and
dihydrotestosterone consisting of four main domains, the N-terminal domain, DNA-binding …

Novel drugs, drug sequences and combinations have improved the outcome of prostate
cancer in recent years. The latest approvals include abiraterone acetate, enzalutamide and …

Various preclinical models have been developed to clarify the pathophysiology of prostate
cancer (PCa). Traditional PCa cell lines from clinical metastatic lesions, as exemplified by …

Activation of the androgen receptor (AR) and AR-driven transcriptional programs is central to
the pathophysiology of prostate cancer. Despite successful translational efforts in targeting …

We report small molecular PROTAC compounds targeting the androgen receptor N-terminal
domain (AR-NTD), which were obtained by tethering AR-NTD antagonists and different …

Nuclear receptors (NRs) are transcription factors actively involved in many aspects of human
physiology and pathology, serving as sensors of stimuli, master regulators of downstream …

Prostate cancer is the second most common malignancy in men and androgen deprivation
therapy is the first‐line therapy. However, most cases will eventually develop castration …

The refractory of castration-resistant prostate cancer (CRPC) is mainly reflected in drug
resistance. The current research on the resistance mechanism of CRPC is still in its infancy …

Metastatic castration-resistant prostate cancer (mCRPC) is a malignant and lethal disease
caused by relapse after androgen-deprivation (ADT) therapy. Since enzalutamide is …